2,586 reports of this reaction
6.6% of all ERYTHROPOIETIN reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for ERYTHROPOIETIN, manufactured by Janssen Products, LP. There are 2,586 FDA adverse event reports linking ERYTHROPOIETIN to DEATH. This represents approximately 6.6% of all 39,177 adverse event reports for this drug.
Patients taking ERYTHROPOIETIN who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among ERYTHROPOIETIN users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for ERYTHROPOIETIN:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 2,586 FDA reports for ERYTHROPOIETIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 6.6% of all adverse event reports for ERYTHROPOIETIN, making it one of the most commonly reported side effect.
If you experience death while taking ERYTHROPOIETIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.